Skip to content
value.today

Cullinan Therapeutics, Inc.

CGEM
No market cap data
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-220 M
SEC filing
Employees
109
As of December 31, 2025
SEC filing

Cullinan Therapeutics, Inc. in brief

Cullinan Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It employs about 109 people and Nadim Ahmed is its chief executive. Its shares trade under the symbol CGEM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cullinan Therapeutics, Inc.

CLN-978 is a CD19xCD3 bispecific T cell engager that we are developing for autoimmune diseases. In the Phase 1 OUTRACE Program, CLN-978 is being evaluated in patients with systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease. The OUTRACE SLE Study is an ongoing global Phase 1 clinical trial in patients with moderate to severe SLE. The OUTRACE RA Study is a Phase 1 clinical trial in patients with active, difficult-to-treat RA, which is ongoing in Europe. We plan to share initial clinical data in SLE and RA in the second quarter of 2026 and repeat dosing data in RA in the third quarter of 2026. The OUTRACE SjD Study is an ongoing global Phase 1 clinical trial in patients with active, moderate to severe Sjögren’s disease. We plan to share initial clinical data in Sjögren’s disease in the fourth quarter of 2026.

From the company's annual report filed with the US SEC: read the report

Cullinan Therapeutics, Inc. timeline

5 events, 2020–2024
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. ✎
    Renamed Cullinan Management, Inc.
    Formerly Cullinan Oncology, LLC.
  5. 🔔
    Initial public offering as Cullinan Management, Inc.
    Final prospectus filed with the SEC on 11 January 2021; shares registered for exchange trading on 6 January 2021.
  6. ✎
    Renamed Cullinan Oncology, Inc.
    Formerly Cullinan Management, Inc..
  7. 2024
  8. ✎
    Renamed Cullinan Therapeutics, Inc.
    Formerly Cullinan Oncology, Inc..

Events of Cullinan Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-53.8%
Liabilities / assets
8.8%
R&D / revenue
304.9%
Profit per employee
$-2.0 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-52M—FY20Fiscal year ending Dec 2021: revenue $19M, net income $-66M$19MFY21Fiscal year ending Dec 2022: revenue —, net income $111M—FY22Fiscal year ending Dec 2023: revenue —, net income $-153M—FY23Fiscal year ending Dec 2024: revenue —, net income $-167M—FY24Fiscal year ending Dec 2025: revenue —, net income $-220M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-242M$-220M—
Dec 2024——$-197M$-167M—
Dec 2023——$-191M$-153M—
Dec 2022——$145M$111M—
Dec 2021$19M—$-68M$-66M-346.2%
Dec 2020——$-60M$-52M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-176M$0M$-176M——
Dec 2024$-145M$0M$-145M——
Dec 2023$-134M$0M$-134M$-3.69—
Dec 2022$-127M$1M$-128M$2.38—
Dec 2021$-43M$0M$-43M$-1.52—
Dec 2020$-30M$0M$-30M$-2.60—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-48M—Dec ’24Three months to Mar 2025: revenue —, net income $-49M—Mar ’25Three months to Jun 2025: revenue —, net income $-70M—Jun ’25Three months to Sep 2025: revenue —, net income $-51M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-51M—Dec ’25Three months to Mar 2026: revenue —, net income $-50M—Mar ’26Three months to Jun 2026: revenue —, net income $-54M—Jun ’26Three months to Sep 2026: revenue —, net income $-49M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-49M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Cullinan Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-242 M
Net income
$-220 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$448 M
Total liabilities
$40 M
Total equity
$409 M

As of December-2025

Top 100 institutional investors in Cullinan Therapeutics, Inc.#

As of Sep 30, 2026
182 institutions held 70.1 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 71.4%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cullinan Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1MPM Bioimpact LLC9,721,081-10,260 (-0.11%)14.97%$149 MNov 16, 2026
2Lynx1 Capital Management LP8,963,5000 (0.00%)13.81%$138 MNov 16, 2026
3BVF Inc/il5,750,6830 (0.00%)8.86%$88 MNov 16, 2026
4BlackRock, Inc.5,319,313+86,547 (+1.65%)8.19%$82 MNov 13, 2026
5Price T Rowe Associates Inc /MD/4,091,640+265,690 (+6.94%)6.30%$63 MNov 16, 2026
6Kynam Capital Management, LP3,114,1320 (0.00%)4.80%$48 MNov 16, 2026
7Vanguard Capital Management LLC2,641,522+27,456 (+1.05%)4.07%$41 MNov 13, 2026
8State Street Corp2,604,105-1,064,522 (-29.02%)4.01%$40 MNov 12, 2026
9RTW Investments, LP2,364,3470 (0.00%)3.64%$36 MNov 16, 2026
10Siren, L.L.C.1,793,410-100,000 (-5.28%)2.76%$28 MNov 12, 2026
11Geode Capital Management, LLC1,448,600-98,709 (-6.38%)2.23%$22 MNov 6, 2026
12Blue Owl Capital Holdings LP1,399,899-139,865 (-9.08%)2.16%$21 MNov 13, 2026
13Venrock Adviser, LLC1,379,9650 (0.00%)2.13%$21 MNov 16, 2026
14Dimensional Fund Advisors LP1,084,765+38,071 (+3.64%)1.67%$17 MNov 4, 2026
15Goldman Sachs Group Inc988,963-12,635 (-1.26%)1.52%$15 MNov 16, 2026
16Elmind Capital, LP962,792+272,792 (+39.54%)1.48%$15 MNov 16, 2026
17Boothbay Fund Management, LLC953,126-129,485 (-11.96%)1.47%$15 MNov 16, 2026
18Affinity Asset Advisors, LLC875,7600 (0.00%)1.35%$13 MNov 13, 2026
19Fisher Asset Management, LLC800,961+764,963 (+2125.02%)1.23%$12 MNov 6, 2026
20Boone Capital Management LLC690,814-13,628 (-1.93%)1.06%$11 MNov 16, 2026
21Morgan Stanley644,639+15,604 (+2.48%)0.99%$10 MNov 13, 2026
22Vanguard Portfolio Management LLC643,491-95,250 (-12.89%)0.99%$10 MNov 13, 2026
23Twin Focus Capital Partners, LLC595,4890 (0.00%)0.92%$9 MNov 13, 2026
24Northern Trust Corp558,159-12,921 (-2.26%)0.86%$9 MNov 16, 2026
25Charles Schwab Investment Management Inc506,077+42,043 (+9.06%)0.78%$8 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Cullinan Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26AQR Capital Management LLC498,566-82,772 (-14.24%)0.77%$8 MNov 16, 2026
27Boxer Capital Management, LLC450,000New0.69%$7 MNov 16, 2026
28Bank Of America Corp /de/415,972-94,353 (-18.49%)0.64%$6 MNov 16, 2026
29TCG Crossover Management, LLC406,7860 (0.00%)0.63%$6 MNov 16, 2026
30Deutsche Bank AG\377,837-5,003 (-1.31%)0.58%$6 MNov 6, 2026
31Vanguard Fiduciary Trust Co376,124+12,988 (+3.58%)0.58%$6 MNov 13, 2026
32FMR LLC336,451+96,336 (+40.12%)0.52%$5 MNov 10, 2026
33Great Point Partners LLC300,0000 (0.00%)0.46%$5 MNov 16, 2026
34Renaissance Technologies LLC290,011-36,800 (-11.26%)0.45%$4 MNov 12, 2026
35Connor, Clark & Lunn Investment Management Ltd.286,096-6,404 (-2.19%)0.44%$4 MNov 10, 2026
36Invesco Ltd.283,144+139,592 (+97.24%)0.44%$4 MNov 12, 2026
37Jpmorgan Chase & Co273,316-9,315 (-3.30%)0.42%$4 MNov 12, 2026
38Wellington Management Group LLP262,713+97,997 (+59.49%)0.40%$4 MNov 16, 2026
39Bleichroeder LP250,0000 (0.00%)0.39%$4 MNov 13, 2026
40UBS Group AG229,203-19,424 (-7.81%)0.35%$4 MNov 10, 2026
41Two Sigma Investments, LP219,719-52,862 (-19.39%)0.34%$3 MNov 16, 2026
42Trexquant Investment LP209,314+57,151 (+37.56%)0.32%$3 MNov 16, 2026
43Apis Capital Advisors, LLC192,000+112,000 (+140.00%)0.30%$3 MNov 13, 2026
44Moore Capital Management, LP181,306-8,640 (-4.55%)0.28%$3 MNov 16, 2026
45Barclays PLC177,595+33,650 (+23.38%)0.27%$3 MNov 6, 2026
46HighVista Strategies LLC173,895New0.27%$3 MNov 13, 2026
47Bank of New York Mellon Corp173,387+2,356 (+1.38%)0.27%$3 MNov 5, 2026
48Nuveen, LLC167,014-304,933 (-64.61%)0.26%$3 MNov 10, 2026
49American Century Companies Inc158,532+2,215 (+1.42%)0.24%$2 MNov 12, 2026
50Susquehanna Portfolio Strategies, LLC121,561-112,281 (-48.02%)0.19%$2 MNov 16, 2026
51Quantinno Capital Management LP121,425+11,549 (+10.51%)0.19%$2 MNov 13, 2026
52PFM Health Sciences, LP104,715-87,727 (-45.59%)0.16%$2 MNov 16, 2026
53Informed Momentum Co LLC104,075New0.16%$2 MNov 16, 2026
54Raymond James Financial Inc98,240New0.15%$2 MNov 12, 2026
55Creative Planning96,738+10,280 (+11.89%)0.15%$1 MNov 2, 2026
56Woodline Partners LP96,572New0.15%$1 MNov 16, 2026
57UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC95,456+11,278 (+13.40%)0.15%$1 MNov 16, 2026
58Knott David M Jr95,369+26,187 (+37.85%)0.15%$1 MNov 12, 2026
59Manufacturers Life Insurance Company, The83,507+6,796 (+8.86%)0.13%$1 MNov 13, 2026
60Rhumbline Advisers82,612+3,682 (+4.66%)0.13%$1 MNov 10, 2026
61Weiss Asset Management LP81,762New0.13%$1 MNov 16, 2026
62TD Asset Management Inc80,6280 (0.00%)0.12%$1 MNov 13, 2026
63Longaeva Partners L.P.79,751+14,966 (+23.10%)0.12%$1 MNov 16, 2026
64Swiss National Bank77,600+1,600 (+2.11%)0.12%$1 MNov 12, 2026
65Ellsworth Advisors, LLC74,856New0.12%$1 MOct 15, 2026
66Susquehanna International Group, LLP71,351+45,261 (+173.48%)0.11%$1 MNov 16, 2026
67Mariner, LLC68,182-6,091 (-8.20%)0.10%$1 MNov 12, 2026
68Tidal Investments LLC67,125+4,299 (+6.84%)0.10%$1 MNov 13, 2026
69Tema Etfs LLC67,125+4,299 (+6.84%)0.10%$1 MOct 16, 2026
70Algert Global LLC64,021+27,170 (+73.73%)0.10%$1 MNov 17, 2026
71Alliancebernstein L.P.63,460-11,790 (-15.67%)0.10%$1 MNov 16, 2026
72Martingale Asset Management L P61,9380 (0.00%)0.10%$1 MNov 12, 2026
73Kennedy Capital Management LLC58,446+5,436 (+10.25%)0.09%$1 MNov 13, 2026
74Corient Private Wealth LP53,909-968 (-1.76%)0.08%$1 MNov 16, 2026
75Rafferty Asset Management, LLC53,230-12,862 (-19.46%)0.08%$1 MNov 13, 2026
76State Of Wisconsin Investment Board53,055+33,005 (+164.61%)0.08%$1 MNov 16, 2026
77Citadel Advisors LLC52,838-344,646 (-86.71%)0.08%$1 MNov 16, 2026
78Franklin Templeton Inc42,541+196 (+0.46%)0.07%$1 MNov 12, 2026
79Engineers Gate Manager LP42,384-110,666 (-72.31%)0.07%$1 MNov 16, 2026
80California State Teachers Retirement System40,2530 (0.00%)0.06%$1 MNov 13, 2026
81Vanguard Global Advisers, LLC38,824+2,047 (+5.57%)0.06%$1 MNov 13, 2026
82Massachusetts Financial Services Co /ma/38,643+6,930 (+21.85%)0.06%$1 MNov 12, 2026
83HRT Financial LP38,156New0.06%$1 MNov 13, 2026
84MetLife Investment Management, LLC35,7460 (0.00%)0.06%$1 MNov 16, 2026
85Prudential Financial Inc35,293-132,262 (-78.94%)0.05%$1 MNov 16, 2026
86Squarepoint Ops LLC33,691-134,426 (-79.96%)0.05%$1 MNov 9, 2026
87MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.33,081-2,454 (-6.91%)0.05%$1 MNov 16, 2026
88Tudor Investment Corp Et Al32,176+9,658 (+42.89%)0.05%$0 MNov 16, 2026
89VANGUARD ASSET MANAGEMENT, Ltd31,656-481 (-1.50%)0.05%$0 MNov 13, 2026
90Russell Investments Group, Ltd.31,320+2,736 (+9.57%)0.05%$0 MNov 6, 2026
91XTX Topco Ltd30,390-46,575 (-60.51%)0.05%$0 MNov 16, 2026
92BNP Paribas Financial Markets29,553+20,065 (+211.48%)0.05%$0 MNov 12, 2026
93Citigroup Inc28,341-96,068 (-77.22%)0.04%$0 MNov 4, 2026
94Legal & General Group Plc27,4770 (0.00%)0.04%$0 MNov 16, 2026
95Aquatic Capital Management LLC27,135New0.04%$0 MNov 16, 2026
96Mercer Global Advisors Inc /adv26,930+5,008 (+22.84%)0.04%$0 MNov 16, 2026
97Millennium Management LLC25,633-320,599 (-92.60%)0.04%$0 MNov 16, 2026
98Panagora Asset Management Inc24,3960 (0.00%)0.04%$0 MNov 12, 2026
99Jupiter Research Capital (Asia) Ltd23,474New0.04%$0 MNov 16, 2026
100Virtus Investment Advisers, LLC23,163-720 (-3.01%)0.04%$0 MNov 12, 2026

All 182 institutional investors, with who bought and sold →

Mutual funds holding Cullinan Therapeutics, Inc.#

153 funds hold shares worth $292 M (about 25.4% of the company). Since their previous reports 94 added shares and 27 sold, buying $68 M net.
Mutual funds holding Cullinan Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.2.38 M$43 M3.7%0.40%+82%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.93 M$35 M3.0%<0.01%+4.0%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.58 M$29 M2.4%0.03%+20%Jun 30, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.1.02 M$19 M1.6%0.13%+140%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.621,218$11 M0.96%0.01%+9.0%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC660,987$11 M1.0%0.03%+24%Jul 31, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.583,803$11 M0.90%0.09%−15%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors562,565$10 M0.87%0.07%+22%Jun 30, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc.559,800$10 M0.86%0.10%+88%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors318,933$6 M0.49%0.06%−1.4%Jun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.303,486$5 M0.47%0.02%newJul 31, 2026
🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC301,774$5 M0.46%0.12%−35%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.277,141$5 M0.43%0.03%+3.6%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC266,914$4 M0.41%0.01%−1.7%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.246,130$4 M0.38%0.02%−1.6%May 31, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC211,090$4 M0.33%0.07%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors202,566$4 M0.31%0.24%+49%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP196,482$3 M0.30%0.04%+0.4%Jul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP188,192$3 M0.29%0.02%−6.5%Jul 31, 2026
🇺🇸 T. Rowe Price Small-Mid Cap ETFT. Rowe Price Associates, Inc.156,443$3 M0.24%0.11%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP170,697$3 M0.26%<0.01%+4.4%Jul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.146,560$2 M0.23%0.03%+25%Jul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP142,879$2 M0.22%0.01%+53%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust133,270$2 M0.21%0.08%+11%May 31, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc.115,618$2 M0.18%0.11%+100%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC113,081$2 M0.17%0.03%+38%Jun 30, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.104,413$2 M0.16%0.06%+122%Jun 30, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors115,107$2 M0.18%0.05%+7.1%Jul 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.114,553$2 M0.18%0.10%+455%May 31, 2026
🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC102,876$2 M0.16%0.41%newMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC97,554$2 M0.15%<0.01%no changeMay 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC93,627$2 M0.14%0.06%+0.5%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC84,571$2 M0.13%0.07%+26%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.88,087$1 M0.14%<0.01%−0.8%May 31, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.76,920$1 M0.12%0.11%−5.7%Jun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC80,791$1 M0.12%0.27%+8.0%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC80,186$1 M0.12%0.03%+23%Jul 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors72,163$1 M0.11%<0.01%+2.3%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC78,550$1 M0.12%<0.01%+5.9%May 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC74,579$1 M0.11%<0.01%−33%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC65,812$1 M0.10%0.03%+21%Jun 30, 2026
🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC63,185$1 M0.10%0.10%+79%Jun 30, 2026
🇺🇸 Tema Oncology ETFTema ETFs LLC62,826$1 M0.10%0.59%+33%May 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.54,308$1 M0.08%0.06%newJun 30, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.51,823$1 M0.08%0.08%−6.7%Jun 30, 2026
🇺🇸 Bridge Builder Tax Managed Small/Mid Cap FundOLIVE STREET INVESTMENT ADVISERS LLC51,795$1 M0.08%0.03%no changeJun 30, 2026
🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc.46,451$1 M0.07%0.12%+146%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation43,000$1 M0.07%0.03%+18%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.42,900$1 M0.07%0.10%no changeJun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP46,694$1 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.41,929$1 M0.06%0.11%newJun 30, 2026
🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation40,971$1 M0.06%0.07%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.42,461$1 M0.07%0.05%+5.2%May 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC35,850$1 M0.06%0.03%+48%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC39,408$1 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC37,131$1 M0.06%<0.01%newMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.32,552$1 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC32,170$1 M0.05%0.03%+66%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.34,598$1 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.30,710$1 M0.05%<0.01%+26%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.30,582$1 M0.05%0.03%+27%Jun 30, 2026
🇺🇸 Optimize Strategy Index ETFSound Capital Solutions, LLC28,061$1 M0.04%0.18%−0.3%Jun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP30,828$1 M0.05%<0.01%+12%Jul 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.30,330$0 M0.05%<0.01%+1.6%May 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC28,892$0 M0.04%0.03%+24%Jul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC28,834$0 M0.04%<0.01%+11%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC23,711$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP25,072$0 M0.04%<0.01%+50%Jul 31, 2026
🇺🇸 AST PGIM Aggressive Multi-Asset PortfolioAST Investment Services, Inc.22,400$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC21,069$0 M0.03%0.06%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC20,683$0 M0.03%0.03%+38%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC20,264$0 M0.03%0.03%+10%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company21,532$0 M0.03%0.03%no changeMay 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.19,400$0 M0.03%0.01%+7.2%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC18,921$0 M0.03%0.11%−14%Jun 30, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC18,923$0 M0.03%0.09%newJun 30, 2026
🇺🇸 MFS Blended Research Small Cap Equity FundMASSACHUSETTS FINANCIAL SERVICES COMPANY20,617$0 M0.03%0.10%newMay 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC19,730$0 M0.03%0.01%+8.8%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC17,375$0 M0.03%0.03%+30%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors16,625$0 M0.03%<0.01%−0.8%Jun 30, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC23,146$0 M0.04%0.17%—Apr 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.16,384$0 M0.03%0.02%no changeJun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC17,979$0 M0.03%<0.01%+22%Jul 31, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP17,018$0 M0.03%<0.01%+127%Jul 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC15,200$0 M0.02%0.11%no changeJun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP16,447$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company15,668$0 M0.02%0.10%newMay 31, 2026
🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust15,101$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC13,570$0 M0.02%0.11%+40%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS13,415$0 M0.02%0.03%+24%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC12,361$0 M0.02%0.03%+26%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC12,273$0 M0.02%0.03%+13%Jun 30, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation11,564$0 M0.02%0.09%−5.4%Jun 30, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC10,800$0 M0.02%0.11%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.9,503$0 M0.01%0.03%+26%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC9,481$0 M0.01%0.04%+18%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC10,351$0 M0.02%0.01%+30%Jul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.9,227$0 M0.01%0.03%+42%Jun 30, 2026
🇺🇸 iShares Morningstar Small-Cap Value ETFBlackRock Fund Advisors10,177$0 M0.02%0.02%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC8,166$0 M0.01%0.03%+27%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cullinan Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$2.5 M
29 sales, 5 insiders
Net, 12 months
-$2.5 M
open market only
Insiders on file
27
since
$13.3 M-$1.8 M$0Dec 2023: bought $0 (0 trades), sold $127 K (11 trades)Dec 23Jan 2024: bought $0 (0 trades), sold $1.1 M (4 trades)Feb 2024: bought $0 (0 trades), sold $647 K (1 trades)May 2024: bought $0 (0 trades), sold $1.8 M (3 trades)MayJul 2024: bought $0 (0 trades), sold $131 K (1 trades)Sep 2024: bought $0 (0 trades), sold $145 K (1 trades)Nov 2024: bought $0 (0 trades), sold $125 K (1 trades)NovDec 2024: bought $0 (0 trades), sold $290 K (5 trades)Jan 2025: bought $0 (0 trades), sold $50 K (1 trades)Feb 2025: bought $0 (0 trades), sold $181 K (4 trades)FebOct 2025: bought $13.3 M (8 trades), sold $0 (0 trades)Nov 2025: bought $0 (0 trades), sold $49 K (1 trades)Dec 2025: bought $0 (0 trades), sold $258 K (7 trades)DecJan 2026: bought $0 (0 trades), sold $49 K (1 trades)Feb 2026: bought $0 (0 trades), sold $885 K (13 trades)Mar 2026: bought $0 (0 trades), sold $125 K (1 trades)MarMay 2026: bought $0 (0 trades), sold $117 K (2 trades)Jul 2026: bought $0 (0 trades), sold $143 K (1 trades)Aug 2026: bought $0 (0 trades), sold $608 K (1 trades)AugSep 2026: bought $0 (0 trades), sold $173 K (1 trades)Nov 2026: bought $0 (0 trades), sold $49 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Cullinan Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jennifer MichaelsonChief Scientific OfficerOption exercise10b5-1 plan+3,805$4.300$16 K162,649Form 4
filed Jennifer MichaelsonChief Scientific OfficerSell10b5-1 plan-4,000$12.36$49 K158,649Form 4
filed Jennifer MichaelsonChief Scientific OfficerOption exercise10b5-1 plan+4,000$4.300$17 K166,844Form 4
filed Jennifer MichaelsonChief Scientific OfficerSell10b5-1 plan-8,000$21.57$173 K158,844Form 4
filed Jennifer MichaelsonChief Scientific OfficerOption exercise10b5-1 plan+30,000$4.300$129 K192,844Form 4
filed Jennifer MichaelsonChief Scientific OfficerSell10b5-1 plan-30,000$20.26$608 K162,844Form 4
filed Jennifer MichaelsonChief Scientific OfficerOption exercise10b5-1 plan+4,000$4.300$17 K170,844Form 4
filed Jennifer MichaelsonChief Scientific OfficerSell10b5-1 plan-8,000$17.82$143 K162,844Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cullinan Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q4 2020
$6.4M
Q4 2021

Stock splits: 1-for-1 split in the period to

Cullinan Therapeutics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2020Q4 2021$6.4M
Q3 2020Q3 2021$0M
Q2 2020Q2 2021$0M
Q1 2020Q1 2021$0.2M

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cullinan Therapeutics, Inc. scorecard#

Passes 1 of the 6 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$220 M-$220 M in fiscal 2025 against -$52 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$220 MNet income -$220 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-44.0%-44.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities10.2×Current ratio 10.25 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cullinan Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cullinan Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue———0190
Research and development187143148925843
General and administrative545442402917
Operating expenses2421971911328760
Operating income−242−197−191145−68−60
Interest and finance income2230226.60.50.9
Other non-operating income (expense)−0.4−0.20.20.1−0.0−0.0
Income before tax−220−167−169151−67—
Income tax00.1−14420—
Net income including minority interests−220−168−155109−67−59
Minority interests' share of net income0−0.2−1.9−2.0−1.9−7.7
Net income attributable to shareholders−220−167−153111−66−52
Earnings per share, basic——-3.692.46-1.52-2.60
Earnings per share, diluted——-3.692.38-1.52-2.60
Shares, weighted average (basic)——424543—
Shares, weighted average (diluted)——424743r20
Balance sheet
Cash and cash equivalents88839815660168
Short-term investments29031636931123142
Other current assets——3.90.6——
Current assets387415480474297212
Property, plant and equipment0.40.71.01.20.10.1
Right-of-use (leased) assets2.61.72.54.10—
Long-term investments582040811400
Total assets448622484561437215
Accounts payable0.81.72.52.73.29.7
Current liabilities383128221214
Lease liabilities (non-current)1.90.82.23.60—
Total liabilities403130261214
Retained earnings−588−368−201−48−159−93
Shareholders' equity409590454535425199
Minority interests000.200.41.3
Total equity409590454535425200r
Total liabilities and equity448622484561437215
Shares outstanding605943464430r
Cash-flow statement
Depreciation and amortization0.30.30.30.10.10.1
Share-based compensation363830282415
Cash from operating activities−176−145−134−127−43−30
Capital expenditure−0.00−0.2−1.10−0.0
Acquisitions, net of cash acquired—————−1.5
Cash from investing activities180−13636249−334−5.4
Shares issued0263380r3.3145
Shares bought back—————−6.6
Cash from financing activities1.126641−26269140
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Cullinan Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$5.1 M
Nadim Ahmed
Other top executives, average
$2.2 M
the CEO earned 2.4× this
$100 invested is now
$98
Cullinan Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Nadim Ahmed$5.1 M$2.3 M$2.2 M$98
2024Mr. Ahmed$7.7 M$8.9 M$3.8 M$115
2023Mr. Ahmed$4.0 M−$185 K$2.3 M$96590

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Cullinan Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Material agreement 1 · Agreement ended 1 · Shareholder vote 2 · Results announced 10

Cullinan Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Agreement ended8-K
Results announced8-K
Directors and officersResults announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

H-1B hiring at Cullinan Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2020 for 1 positions, at a median wage of $195 K a year.

Certified, FY2020
1
#1,984 among companies on value.today
Worker positions
1
Median wage offered
$195 K
a year, full-time
Applications filed
1
Cullinan Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2020
Job titlePositionsMedian wage offered
Director, InnovationNatural Sciences Managers1$195 K

Where: Cambridge, MA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Cullinan Management, Inc.

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cullinan Therapeutics, Inc.🇺🇸————
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cullinan Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cullinan Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cullinan Therapeutics, Inc.? Suggest a correction